BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2126036)

  • 1. Meningism in a ten-month-old infant during OKT3 therapy.
    Rizzo JD; Rowe SA
    J Heart Transplant; 1990; 9(6):727-8. PubMed ID: 2126036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of refractory, recurrent heart rejection with multiple courses of OKT3.
    Frist WH; Gerhardt EB; Merrill WH; Atkinson JB; Eastburn TE; Stewart JR; Hammon JW; Bender HW
    J Heart Transplant; 1990; 9(6):724-6. PubMed ID: 2126035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinoid necrosis of a temporal artery complicating the treatment of refractory cardiac allograft rejection with murine monoclonal CD3 antibody (OKT3).
    Hammond EH; Watson FS; Bristow MR; O'Connell JB; Gilbert EM; Doty DB; Renlund DG
    J Heart Transplant; 1990; 9(3 Pt 1):236-8. PubMed ID: 2113090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nosocomial aseptic meningitis associated with administration of OKT3.
    Martin MA; Massanari RM; Nghiem DD; Smith JL; Corry RJ
    JAMA; 1988 Apr; 259(13):2002-5. PubMed ID: 3126308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss.
    O'Connell JB; Renlund DG; Hammond EH; Wittwer CT; Yowell RL; DeWitt CW; Jones KW; Gay WA; Menlove RL; Bristow MR
    J Heart Lung Transplant; 1991; 10(2):217-21; discussion 221-2. PubMed ID: 1903303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
    Macris MP; Frazier OH; Lammermeier D; Radovancevic B; Duncan JM
    J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments.
    Kremer AB; Barnes L; Hirsch RL; Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):54-7. PubMed ID: 3105141
    [No Abstract]   [Full Text] [Related]  

  • 8. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation.
    Hegewald MG; O'Connell JB; Renlund DG; Lee HR; Burton NA; Karwande SV; Jones KW; Lassetter JE; Bristow MR
    J Heart Transplant; 1989; 8(4):303-9; discussion 309-10. PubMed ID: 2504897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction immunosuppression with OKT3 monoclonal antibody in cardiac transplant recipients.
    Pulpón LA; Domínguez P; Cháfer M; Segovia J; Crespo MG; Pradas G; Burgos R; Figuera D
    Transplant Proc; 1990 Oct; 22(5):2319. PubMed ID: 2120816
    [No Abstract]   [Full Text] [Related]  

  • 10. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation.
    Kormos RL; Herlan DB; Armitage JM; Stein K; Kaufman C; Zeevi A; Duquesnoy R; Hardesty RL; Griffith BP
    J Heart Transplant; 1990; 9(1):1-9, discussion 9-10. PubMed ID: 2107288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some aspects of changed histopathologic appearance of acute rejection in cardiac allografts after prophylactic application of OKT3.
    Kemnitz J; Cremer J; Schaefers HJ; Restrepo-Specht I; Haverich A; Uysal A; Heublein B; Wirth S
    J Heart Lung Transplant; 1991; 10(3):366-72. PubMed ID: 1906746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
    Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
    J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
    Toyoda M; Galfayan K; Wachs K; Czer L; Jordan SC
    Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OKT3 treatment of cardiac allograft rejection.
    Haverty TP; Sanders M; Sheahan M
    J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
    Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using OKT3 to reverse cardiac allograft rejection.
    Rogers KR; Sinnott JT; Ferguson JE
    Heart Lung; 1989 Sep; 18(5):490-6. PubMed ID: 2506149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac allograft cellular rejection during OKT3 prophylaxis in the absence of sensitization.
    Moore CK; O'Connell JB; Renlund DG; Bristow MR; Hammond EH
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1055-8. PubMed ID: 1899151
    [No Abstract]   [Full Text] [Related]  

  • 19. Orthoclone OKT3 and cardiac transplantation: an overview.
    Mahon PM
    Crit Care Nurse; 1991 Sep; 11(8):42-7, 50. PubMed ID: 1909947
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.